This inventor holds 2 USPTO granted patents and 1 published patent application and 1 EPO patent. Top assignee: Sysmex Corporation. Active years: 2020-2023.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
Company Filing History:
Years Active: 2020-2023
Title: Kenta Noda: Innovator in Cyclin-Dependent Kinase Research
Introduction
Kenta Noda is a prominent inventor based in Kobe, Japan. He has made significant contributions to the field of biochemistry, particularly in the area of cyclin-dependent kinases. With a total of 2 patents, Noda's work focuses on improving the understanding and treatment of various diseases through innovative methodologies.
Latest Patents
Noda's latest patents include a method for determining sensitivity to cyclin-dependent kinase 4/6 inhibitors. This method involves comparing the activity of CDK4 and CDK6 in a sample from a subject against a threshold level. If the activity is below this threshold, the subject is determined to be insensitive to the inhibitor. Another notable patent is for a cyclin-dependent kinase substrate, which includes a polypeptide with a specific amino acid sequence. This substrate is designed to enhance the understanding of kinase activity and its implications in cellular processes.
Career Highlights
Kenta Noda is currently associated with Sysmex Corporation, where he continues to advance his research in the field of biochemistry. His work has been instrumental in developing new approaches to understanding kinase functions and their roles in various biological processes.
Collaborations
Noda collaborates with esteemed colleagues such as Noriko Yokose and Naoki Nishiyama. Their combined expertise contributes to the innovative research being conducted at Sysmex Corporation.
Conclusion
Kenta Noda's contributions to the field of cyclin-dependent kinases are noteworthy and impactful. His innovative patents and ongoing research continue to pave the way for advancements in biochemistry and medicine.
Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile
